Medtronic to launch new renal denervation study based on positive trial data

Medtronic has announced plans to proceed with a new study assessing the benefits of renal denervation in the treatment of high blood pressure.

The decision to move ahead with the trial comes in response to the positive findings of SPYRAL HTN-OFF MED, a study that demonstrated statistically significant and clinically important blood pressure reductions among patients treated with renal denervation across both office and ambulatory systolic and diastolic measurements.

Additionally, there were no reported cases of new or worsening renal failure, vascular complications or other major adverse events, confirming the safety of the renal denervation procedure.

SPYRAL HTN-OFF MED improved upon the earlier SYMPLICITY HTN-3 by taking steps to ensure patients remained off their medication throughout the duration of the study, while also leveraging new anatomical insights to make the renal nerves easier to access.

Sean Salmon, senior vice-president and president of Medtronic's coronary and structural heart division, said: "We are committed to continuing our mission to realise the full potential of this procedure to help address an unmet need for the more than one billion people worldwide living with high blood pressure."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.